

February 9, 2024

The Honorable Debbie Wasserman Schultz United States House of Representatives 270 Cannon House Office Building Washington, DC 20515

The Honorable Mark DeSaulnier
United States House of Representatives
503 Cannon House Office Building
Washington, DC 20515

The Honorable Brian Fitzpatrick
United States House of Representatives
271 Cannon House Office Building
Washington, DC 20515

230 W. Monroe St., Ste. 710 Chicago, IL 60606-4703 USA

main: 312.235.4060 fax: 312.235.4059

The Honorable Amy Klobuchar United States Senate 425 Dirksen Senate Office Building Washington, DC 20510

The Honorable Ben Cardin United States Senate 509 Hart Senate Office Building Washington, DC 20510

Dear Representative Wasserman Schultz, Representative DeSaulnier, Representative Fitzpatrick, Senator Klobuchar, and Senator Cardin:

On behalf of the Society of Gynecologic Oncology (SGO), thank you for introducing the Comprehensive Cancer Survivorship Act (CCSA) (H.R. 4363/S.2213) to improve the future of cancer survivorship care and the quality of life of cancer survivors. SGO joins more than 50 medical and patient organizations in endorsing this legislation, which is truly comprehensive in nature and will benefit patients and survivors of gynecologic cancers through the promotion of screenings, inclusive clinical trials, the implementation of an alternative payment model and address health disparities.

The SGO is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers. Our more than 2,800 members, who include physicians, nurses, and advanced practice providers, represent the oncology team dedicated to the treatment and care of these patients. The society's purpose is to improve care by encouraging research and disseminating knowledge, raising the standards of practice in the prevention and treatment of gynecologic malignancies, and collaborating with other organizations interested in patient care, oncology, and related fields. Ultimately, our vision is to eradicate gynecologic cancers.

In 2024, it is estimated that over 116,000 women would be diagnosed with a gynecologic cancer, including cervical, ovarian, endometrial, vaginal, and vulvar cancers, and more than 33,000 would die.¹ Significant advances have been made in the field of gynecologic oncology, through diligent research and collaboration with patients eager to be involved. However, the incidence of gynecologic cancers is increasing, particularly startling is the increasing incidence of endometrial cancer, and we are seeing stark health care disparities and disproportionate impacts on our most vulnerable citizens and minority populations.











¹ https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2024/2024-cancer-facts-and-figures-acs.pdf

Notably, the 5-year survival rate for most gynecologic cancers is over 65 percent.² Thus, the care for people diagnosed with a gynecologic cancer extends past their diagnosis and includes the transition from cancer treatment to survivorship care. SGO is committed to serving as a resource for care planning and the transition to survivorship and has a <u>Survivorship Toolkit</u> which provides treatment summaries and care plans for patients with gynecologic cancers. As a trusted resource for clinicians involved in surveillance and survival care, SGO understands that survivorship care is multifaceted and applauds the sponsors of the CCSA for compiling a truly comprehensive bill on this topic.

SGO was pleased to see that key pillars of CCSA include care planning and transition, an alternative payment model, navigational services, quality of care initiatives, employment considerations, and educational resources for survivors and health professionals. Each of these pillars are vital to ensuring that patients and survivors receive the best care possible. Ultimately, the key pillars of the CCSA align with SGO's mission regarding the treatment and care of gynecologic cancer patients entering survivorship. For these reasons, we are pleased to endorse this important legislation.

SGO thanks you for your leadership and efforts to improve the future of cancer survivorship care and improve the quality of life of cancer survivors. Should you have any questions or require SGO members' expertise, please don't hesitate to contact Erika Miller, JD, at <a href="mailto:e

Sincerely,

Angeles Alvarez Secord, MD, MHSc

SGO President, 2023-2024

² https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649722/